Nivolumab or capecitabine or combination therapy as adjuvant therapy for triple negative breast cancer (TNBC) with residual disease following neoadjuvant chemotherapy: the OXEL study.
Citation: 2019/04/30/Department: MedStar Georgetown University Hospital ResidentsForm of publication: Poster PresentationYear: 2019Conference information: MedStar Health-Georgetown University Research Symposium, North Bethesda, MD., Fiscal year: FY2019Local accession number: C2019_353Date added to catalog: 2021-01-11Item type | Current library | Collection | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|---|
Poster Presentation | MedStar Authors Catalog | Poster | Available |